Feasibility of serum Cystatin C for predicting Vancomycin concentration in abdominal cancer patients with severe infectious disease

CURRENT STATUS: UNDER REVIEW

BMC Infectious Diseases  BMC Series

Xiaowu Zhang  zhangxiaowu1986@163.com
Tianjin medical University Cancer Institute and Hospital
Corresponding Author
ORCiD: 0000-0002-3751-6348

Donghao Wang
Tianjin Medical University Cancer Institute and Hospital

DOI: 10.21203/rs.2.18049/v1

SUBJECT AREAS  Infectious Diseases  Oncology

KEYWORDS  Vancomycin, Abdominal cancer, Trough concentration, Infection
Abstract

Background: This study was designed to investigate the population pharmacokinetics and impact indicator of vancomycin in abdominal cancer patients complicated with severe infectious disease.

Methods: A total of 78 patients abdominal cancer patients complicated with severe infectious disease were included. Vancomycin serum trough concentrations were measured using the fluorescence polarization immunoassay (FPIA) method. The patients were divided into early and delayed groups based on whether they achieve the target concentration. And clinical factors were compared between two groups.

Results: The average initial therapeutic dose of vancomycin was 15.18±3.29 mg/kg (q12h). The research revealed that the abdominal cancer patients complicated with severe infectious disease had significantly lower initial vancomycin trough concentrations (median [IQR]: 6.90[5.28-11.20] mg/L). Multiple regression analysis revealed that Cys-C was the most important variable for vancomycin target trough achievement. The duration of mechanical ventilation in Early group was considerably shorter compared with group Delayed group (χ²=4.532; p < 0.05; Fig 1E). Propensity score weighting further confirmed that the duration of mechanical ventilation (χ²=6.607; p < 0.05; Fig 1F) and vasoactive agent (χ²=6.106; p < 0.05; Fig 1D) was considerably shorter compared with group Delayed group.

Conclusions: The steady-state initial vancomycin trough concentration was significantly reduced in abdominal cancer patients complicated with severe infectious disease. The baseline Cys-C level measured prior to administration of vancomycin is suggested to be the most suitable parameter to predict whether
vancomycin trough concentration is up to standard dosage.

Introduction

Vancomycin is a bactericidal glycopeptide antibiotic which inhibits bacterial growth by hindering the synthesis of cell wall in bacteria. It has strong antibiotic effect on Gram-positive bacteria. It includes methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterococcus*, or methicillin-resistant *Staphylococcus epidermidis* (MRSE) [1]. The pharmacokinetic-pharmacodynamic breakpoint of vancomycin is defined as the ratio of the area from 0 to 24 hours (area under the curve (AUC) 0–24) under the concentration-time curve to minimal inhibitory concentration (MIC), and is at least 400 h in adults with *Staphylococcus aureus* pneumonia [2]. Intravenous vancomycin mainly combined with albumin and IgA, protein-bound protein is 25% to 50%, almost completely eliminated by the renal pathway. Therefore, the most important factor in determining vancomycin dosage is renal function [3]. Therapeutic drug monitoring (TDM) as an optimizing vancomycin therapy is widely recommended for avoiding secondary clinical complications because of its narrow therapeutic window, such as vancomycin toxicity due to over-dosing or resistance due to under-dosing [3]. Patients with malignant tumors represent a critical population in whom empirical antibacterial therapy deficiency may significantly increase infection-related morbidity and mortality. In addition, previous studies have demonstrated that the pharmacokinetic parameters of cancer patients often exhibit different characteristics compared to non-cancer patients [4] [5], so optimizing drug dosing regimens is critical. Researches have shown that vancomycin has a significantly increased clearance rate in adults with hematologic malignancies compared to adults without malignant tumors, but there is insufficient pharmacokinetic data. [6]
Therefore, we aimed to elucidate the possible effects of this pharmacokinetic difference on conventional vancomycin treatment and conducted a retrospective researcher to study the influencing factors of the trough concentrations for vancomycin dose adjustment in abdominal cancer patients complicated with severe infectious disease.

Methods

Subjects: From February 2014 to June 2017, we retrospectively reviewed 78 patients of abdominal cancer aged more than 18 years who were complicated with severe infectious disease and who were treated in the intensive care unit of Tianjin Cancer Hospital (Tianjin, China). This clinical trial was agreed by the Ethics Committee and approval from the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and complied with the Declaration of Helsinki. And their data were collected from the clinical charts. All patients received vancomycin therapy for more than five estimated terminal disposition half-lives, by which time serum vancomycin levels were supposed to have reached a steady state. Human subjects with poor kidney function (CLcr <50 mL/min), pregnant and lactating women, hemodialysis patients were excluded. Other anti-infective treatments were administered if patient condition needs.

Pharmacokinetic analysis and Vancomycin therapeutic drug monitoring (TDM):

The vancomycin dosage was administered over a 1-hour period. The steady state vancomycin trough concentration was measured prior to subsequent treatment to adjust dose and dose intervals [8]. The target serum vancomycin trough concentrations ranged from 10–15 or 15–20 mg/L[9]. Serum vancomycin
concentrations were measured by FPIA method using a Cobas 6000 c501 analyzer (Roche Diagnostics, China). Meanwhile, the laboratory staff records information about each specimen, including gender, age, body weight, serum creatinine concentration, daily dosage, dose interval, infusion time, sampling time since infusion end and measure concentration for pharmacokinetic analysis.

Data collection:

Demographic data obtained included age, gender, admission diagnosis, acute physiology and chronic health assessment II score (Apache II score) at admission to the ICU. For the treatment program, daily doses, interval time, and the occurrence of acute kidney injury (AKI) and renal replacement therapy (RRT) were recorded. New-onset acute kidney injury was defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) stage II criteria after at least 24 hours and within 7 days of vancomycin administration initiation [10]. The duration of the vasoactive agent, the duration of mechanical ventilation, the duration of the antibiotic, and the 28-day all-cause mortality were also recorded. The definition of clinical outcomes after cessation of the study drug, including clinical success and clinical failure, are shown in Table 1. Finally, inverse probability of treatment weighting (IPTW) was used to measure participants based on the estimated exposure probability (the propensity score) for a given confounding factor to balance the observed confounding factors between the early and delayed groups.

Statistical analysis

Values for categorical variables are given as count (percentage), for continuous variables, as mean±standard deviation or as median [interquartile range]. Pearson $^2$ test was used for categorical variables, and t test was used for continuous variables. Univariate and multivariate analysis is used for covariates associated with target
trough achievement. Survival was estimated by the Kaplan-Meier method and compared using the log-rank test. All statistical analyses were performed using the SPSS statistical package (version 24.0, SPSS Inc., Chicago), \( P \leq 0.05 \) was considered statistically significant.

Results

A total of 78 patients were enrolled, all of whom received recommended standard vancomycin dosage adjustment. Clinical characteristics, pharmacokinetic parameters and clinical outcomes of the included patients were summarized in Table 2 and Table 3. Our research revealed that the abdominal cancer patients complicated with severe infectious disease have a significantly lower initial vancomycin trough concentration (median [IQR]: 6.90[5.28–11.20] mg/L) than the recommended standard vancomycin trough concentrations (10–15 or 15–20 mg/L). The overall relationship between trough concentrations and potential covariates was screened by Univariate and multivariate analysis to explore potential information covariates. There was a strong correlation between vancomycin trough concentration and age, body weight, serum creatinine and serum Cystatin C level (Cys-C) (Table 4). Multivariate regression analysis revealed that the Cys-C was the most important variable for vancomycin target trough achievement (odds ratio, 5.274; 95% CI, 1.780 to 15.627; \( p = 0.003 \) (Table 4).

We divided patients into Early group and Delayed group based on whether the initial trough concentration achieved the target concentration. Although the Clinical outcomes were similar between two groups in Table 5 (e. g., the incidence of new-onset AKI or RRT, clinical success rate, 28-day all-cause mortality), the duration of mechanical ventilation in Early group was considerably shorter compared with
Delayed group ($\chi^2 = 4.532; p < 0.05; \text{Fig 1E}$). Compared with Delayed group, propensity score weighting (IPTW) further confirmed that the duration of mechanical ventilation ($\chi^2 = 6.607; p < 0.05; \text{Fig 1F}$) and vasoactive agent ($\chi^2 = 6.106; p < 0.05; \text{Fig 1D}$) in Early group were considerably decreased.

Discussion

Of these 78 patients, small number of patients achieved the target level. The standard vancomycin dose recommended in the package instructions approved by the Chinese authorities appears to be too low to achieve the target trough concentrations in clinical practice. The reason for this result may be because the standard vancomycin administration algorithm was developed based on data from relatively healthy patients. Therapeutic drug monitoring of vancomycin is widely recommended for clinical treatment\[11]\ [9]. However, few studies have been available to evaluate vancomycin (VCM) pharmacokinetics in abdominal cancer patients complicated with severe infectious disease. The aim of this study was to address the above issues and sought to find clinically useful information to predict and estimate the appropriate dosage of vancomycin. The conclusion is that initial vancomycin trough concentrations are significantly reduced in these patients. We also found that Cys-C was associated with target trough achievement. Accordingly, the traditional standard dose of vancomycin may result in a high risk of failing to achieve the recommended standard vancomycin trough concentrations. This finding confirms the need to design more effective guidelines for individualized vancomycin anti-infective treatment in patients with abdominal cancers with severe infectious diseases.

Previous studies have shown that malignant tumors themselves may have an impact
on VCM PKs [12], in addition to changes in volume of distribution due to edema, peritoneum or pleural effusion. Chang et al. reported a significant increase in VCM clearance (CL) in pediatric cancer patients using the 2-compartment Bayesian PK approach has been reported, which has also been demonstrated in adult hematological malignancies [13]. Meanwhile, there are also different opinions, Omote’s findings suggest that there is no significant differences in estimated VCM clearance between cancer patients and non-cancer patients, indicating that the dosage can be adjusted only by conventional TDM [14]. Nevertheless, Shimada et al. proposed that direct activation of renal organic anion/cation transporters (OCT1/2, OATs) by cytokines such as TNF-α leads to an increase in renal clearance, which is confirmed by in vivo experiments [15] [16].

Severe infectious disease was frequently combined with the development of systemic inflammatory response syndrome (SIRS). This inflammatory response leads to vasodilatation, capillary leakage and the development of hyperdynamic cardiovascular state characterized by third-space, high cardiac output and increased blood flow to the major tissue and organ [17]. As water soluble, vancomycin is primarily cleared by the kidneys. Increased CL is very likely due to increase in renal blood flow, which enhances the elimination of vancomycin by urine and leads to a decrease in plasma vancomycin concentration. And increased volume of distribution (Vd) is usually attributed to the third space induced by SIRS [18], which results in significant overhydration. However, the underlying mechanism for increasing vancomycin CL and Vd still need further studied.

Recently, some studies have proposed augmented renal clearance (ARC) to describe the enhancement of renal elimination of circulating solutes observed in critically ill patients [19]. Most studies have shown that hyperdynamic circulation characterized
by increased renal blood flow and increased in glomerular filtration rate are potential mechanism [20]. Nevertheless, in these studies, no information was given concerning the number of oncological patients in these studies. Previous study found that the risk factors for ARC are age, sepsis, and SIRS [19]. Thus, the increased vancomycin CL observed in this study was very likely to be related to ARC but not oncological status. However Curth et al. had different opinions [21]. They believed that oncological status can also cause occurrence of ARC. Considering that the study is only a case report, this opinion should be treated with caution. In practice, there is no guidance for this treatment and ARC has not been taken seriously in clinical work in China. Clinicians usually do not seriously consider increasing the dose even though dose adjustment is allowed at their discretion and the actual therapeutic drug monitoring results showed very low concentrations. And our research strongly recommends that abdominal cancer patients require higher dose regimens.

In this research, we observed a strong correlation between vancomycin trough concentrations and age, body weight, serum creatinine and especially the Cys-C. This research confirmed the relationship between Cys-C and vancomycin trough concentrations for the first time in abdominal cancer patients. Cys-C is a non-glycosylated, low molecular weight basic protein composed of 120 amino acids [22]. Human Cys-C is a housekeeping gene and is stably produced by all human nucleated cells [22]. In earlier studies, Cys-C was considered to be independent of age, muscle mass or body mass index in healthy individuals [23]. Although previous studies have shown a significant correlation between serum Cys-C levels and malignant progression of colorectal cancer, melanoma and ovarian cancer [24], recent studies confirmed that Cys-C can be very effective in predicting renal function in cancer
patients [25] [26]. These features partially explain the relationship between Cys-C and vancomycin trough concentrations.

This observational study was done on a real-time clinical practice. Since the serum Cys-C is readily available in clinical practice, these parameters may allow physicians and/or pharmacists to predict vancomycin dose requirements in a short period of time. Earlier identification of insufficient vancomycin trough concentrations could be used to optimize antimicrobial adequacy. Earlier initial goal vancomycin trough concentration achievement means shorter duration of mechanical ventilation, and shorter duration of vasoactive agent, which means earlier hemodynamic stability. With this conclusion, clinicians should be able to adjust the dose of vancomycin confidently. For specific dose adjustment algorithm, we need further research. Recently, Erin Frazee et al have confirmed that vancomycin dosing algorithm based on estimated glomerular filtration rate from creatinine and Cys-C levels significantly improved goal trough achievement compared to Cockcroft-Gault creatinine clearance among ICU patients with stable kidney function [27].

There are several potential limitations in research. Firstly, the samples collected in this study were too limited to accurately assess the pharmacokinetics of vancomycin. Secondly, this is single-center and observational study with bias in case selection. Thirdly, inappropriately timed vancomycin trough concentration determination is a general challenge for therapeutic drug monitoring and is present regardless of the vancomycin administration algorithm used.

Conclusion

The serum initial trough concentration of vancomycin was significantly reduced in
abdominal cancer patients complicated with severe infectious disease. Clinicians should pay special attention to changes in vancomycin pharmacokinetic, and higher dosage regimens are needed to ensure clinical effectiveness. The Cys-C level measured prior to vancomycin was administered is considered to be a potentially valuable parameter for predicting whether the vancomycin trough concentration is up to standard. Further, this study is promising, prospective validation of this or a similar Cystatin C-inclusive dosing model is warranted.

Declarations

Acknowledgment

We thank the health professional staff from Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital.

Ethics approval and consent to participate

This retrospective cohort study was agreed by the Ethics Committee and approval from the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and waived the requirement to obtain informed consent

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interest

All authors reported no competing interests.

Funding

The study was supported by a grant from the Oncology and Translational Medicine
of Tianjin Medical University Cancer Institute and Hospital, China (No. 1611). The funders had no role in study design, data collection, data analysis, and data interpretation or writing of the manuscript.

Authors’ Contributions

Xiaowu Zhang and Donghao Wang were involved in the concept, interpretation of the data and writing of the manuscript. Xiaowu Zhang was involved in the statistical analyses and the writing of the manuscript.

References

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE et al: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2011, 52(3):e18–55.

2. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical pharmacokinetics 2004, 43(13):925–942.

3. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2009, 49(3):325–327.

4. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R: Daptomycin
pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrobial agents and chemotherapy 2009, 53(2):428-434.

5.Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM: Population pharmacokinetics of amikacin in patients with haematological malignancies. The Journal of antimicrobial chemotherapy 1999, 44(2):235-242.

6.Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ: Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrobial agents and chemotherapy 2005, 49(12):4934-4941.

7.Fernandez de Gatta Mdel M, Santos Buelga D, Sanchez Navarro A, Dominguez-Gil A, Garcia MJ: Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clinical pharmacokinetics 2009, 48(4):273-280.

8.He J, Mao EQ, Feng J, Jiang HT, Yang WH, Chen EZ: The pharmacokinetics of vancomycin in patients with severe acute pancreatitis. European journal of clinical pharmacology 2016, 72(6):697-702.

9.Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GR: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. The Clinical biochemist Reviews 2010, 31(1):21-24.

10.Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical practice 2012, 120(4):c179-184.

11.Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang KH, Zhang YY et al: Therapeutic drug monitoring of vancomycin: a guideline of the Division of
Therapeutic Drug Monitoring, Chinese Pharmacological Society. The Journal of antimicrobial chemotherapy 2016, 71(11):3020–3025.

12. Sadoh S, Tsuji Y, Tsukamoto K: [Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies]. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 2010, 130(1):69–73.

13. Chang D: Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. The Pediatric infectious disease journal 1995, 14(8):667–673.

14. Omote S, Yano Y, Hashida T, Masuda S, Yano I, Katsura T, Inui K: A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biological & pharmaceutical bulletin 2009, 32(1):99–104.

15. Balkwill F: Tumour necrosis factor and cancer. Nature reviews Cancer 2009, 9(5):361–371.

16. Shimada I, Iwata C, Taga S, Teramachi H, Nomura M, Miyamoto K, Tsuciya H, Wada T, Kimura K, Matsushita R: Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma. Anticancer research 2012, 32(3):823–829.

17. Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D: Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive care medicine 2013, 39(7):1247–1252.

18. del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A: Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive care medicine 2007, 33(2):279–285.

19. Udy AA, Roberts JA, Lipman J: Implications of augmented renal clearance in critically ill patients. Nature reviews Nephrology 2011, 7(9):539–543.

20. He J, Mao E, Jing F, Jiang H, Yang W, Chen E: [Pharmacokinetics of vancomycin in
patients with severe acute pancreatitis and its influencing factors: analysis of 7 years data]. Zhonghua wei zhong bing ji jiu yi xue 2017, 29(6):491-495.

21.Curth HM, Pelc A, Kutting F, Steffen HM: Augmented renal vancomycin clearance in cancer patients: a case report and review of the literature. Oncology research and treatment 2015, 38(4):182-184.

22.Randers E, Erlandsen EJ: Serum cystatin C as an endogenous marker of the renal function—a review. Clinical chemistry and laboratory medicine 1999, 37(4):389-395.

23.Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American journal of kidney diseases: the official journal of the National Kidney Foundation 2001, 37(1):79-83.

24.Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research 2000, 6(2):505-511.

25.Yang F, Li D, Di Y, Zhang Y, Zang Y, Ren J, Yan L, Zhou Z, Liu H, Xu Z: Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia. BioMed research international 2017, 2017:7450459.

26.Ohara G, Miyazaki K, Kurishima K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N: Serum levels of cystatin C in elderly lung cancer patients. Oncology letters 2012, 3(2):303-306.

27.Frazee E, Rule AD, Lieske JC, Kashani KB, Barreto JN, Virk A, Kuper PJ, Dierkhising RA, Leung N: Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. American journal of kidney diseases: the official journal of the National Kidney Foundation 2017, 69(5):658-666.
Tables

Table 1: Clinical outcome definitions after study drug cessation

| Clinical response   | Definition                                                                 |
|--------------------|---------------------------------------------------------------------------|
| Clinical success   | 1. Cure or improvement of all signs and symptoms caused by the infection   |
|                    | 2. No additional antibiotic therapy required                               |
| Clinical failure   | 1. Persistent or worsening of any one of the clinical symptoms             |
|                    | 2. New clinical signs and symptoms of infection                            |
|                    | 3. Other systemic antimicrobial therapy required                            |

Table 2: Vancomycin Levels Achieved and Clinical Outcomes (n=78)
| Characteristics |     |
|-----------------|-----|
| **Sex (male/female)** | 17/61 |
| **Age (years)**   | 65.04±12.72 |
|                  | 65[57-63] |
| **Body weight(kg)** | 24.74±3.68 |
|                  | 79[71.5-86] |
| **Apache II score** | 20.05±2.92 |
|                  | 19[18-22] |
| **SOFA score**    | 13.15±2.25 |
|                  | 13[12-15] |
| **Albumin (g/L)** | 27.89±6.14 |
|                  | 28.20[24.85-32.30] |
| **Serum creatinine (μmol/L)** | 68.74±22.97 |
|                  | 56.0[46.0-84.5] |
| **Cys-C(mg/L)**   | 1.237±0.560 |
|                  | 1.105[0.770-1.418] |

**Cancer type, n(%)**

| Cancer type           |    |
|-----------------------|----|
| Hepatocellular carcinoma | 16(20.5) |
| Pancreatic cancer      | 6(7.7) |
| Colorectal cancer      | 22(28.2) |
| Gastric cancer         | 32(41.0) |
| Gallbladder cancer     | 2(2.6%) |

**Suspected source of infection**

| Source of infection    |    |
|------------------------|----|
| Pulmonary              | 39(50) |
| Intra-abdominal        | 28(35.9) |
| Surgical incision      | 3(3.8) |
| Other/unknown          | 8(10.3) |

**Identified pathogens, n (%)**

- *methicillin-resistant Staphylococcus aureus* | 21(26.9) |
- *methicillin-resistant Staphylococcus epidermidis* | 12(15.4) |
- *Enterococcus* | 35(44.9) |
- Other Gram-positive coccus | 10(12.8) |

Abbreviations: APACHE II, acute physiology and chronic health evaluation II; SOFA,
Sequential Organ Failure Assessment; Cys-C, Cystatin C.

Table 3. Vancomycin Levels Achieved and Clinical Outcomes (n=78)

| Characteristic                                      | n (%)                  |
|-----------------------------------------------------|------------------------|
| Initial dose (daily), n (%)                         |                        |
| 1000–2000 mg                                        | 4 (5.1)                |
| 2001–3000 mg                                        | 50 (64.1)              |
| 3000 mg                                             | 24 (30.8)              |
| Average daily dosage (mg/kg, q12h)                  | 15.18±3.29             |
|                                                     | 15.38[14.29-19.27]     |
| Vancomycin trough concentration, n (%)              |                        |
| 10mg/L                                              | 55 (70.5)              |
| 10-15 mg/L                                          | 15 (19.3)              |
| 15-20 mg/L                                          | 8 (10.3)               |
| Average trough concentration (mg/L)                 | 8.26±5.01              |
|                                                     | 6.90[5.28-11.20]       |
| Duration of vasoactive agent (day)                  | 4[2-5]                 |
| Duration of ventilation (day)                       | 4[3-5]                 |
| Duration of antibiotics (day)                       | 5[5-7]                 |
| Composite outcome of new-onset AKI or RRT           | 7 (9.0)                |
| Clinical success rate, n (%)                        | 58 (74.4)              |
| 28-day all-cause mortality                          | 4 (5.1)                |

Abbreviations: AKI, acute kidney injury; RRT, renal replacement therapy.

Table 4. Univariate and Multivariate Analysis of Covariates Associated With Target Trough Achievement
| Variants                  | Univariate Analysis |                  |                  | Multivariate Analysis |                  |
|--------------------------|---------------------|------------------|------------------|-----------------------|------------------|
|                          | OR                  | 95% CI           | p                | OR                    | 95% CI           |
| Sex                      | 1.470               | 0.423-5.105      | 0.544            |                       |                  |
| Age (years)              | 1.057               | 1.003-1.114      | 0.039*           | 1.152                 | 0.9              |
| Body weight(kg)          | 1.057               | 1.002-1.116      | 0.043*           | 0.929                 | 0.8              |
| Apache II score          | 1.016               | 0.863-1.198      | 0.846            |                       |                  |
| SOFA score               | 1.006               | 0.809-1.250      | 0.959            |                       |                  |
| Albumin (g/L)            | 1.007               | 0.925-1.097      | 0.864            |                       |                  |
| Serum creatinine (μmol/L)| 1.018               | 1.002-1.035      | 0.032*           | 1.018                 | 0.9              |
| Cys-C(mg/L)              | 5.249               | 1.972-13.972     | 0.001*           | 5.274                 | 1.71             |

*p < 0.05

Abbreviations: APACHE II, acute physiology and chronic health evaluation II; SOFA, Sequential Organ Failure Assessment; Cys-C, Cystatin C.

Table 5 Patients’ Baseline Data Before and After Propensity Score Weighting (n=78)
| Characteristics                          | Entire Cohort |
|-----------------------------------------|--------------|
|                                          | Delayed group | Early group | $\chi^2$ | $P$   |
|                                          | (n=55)        | (n=23)      |
| Age, years                              |              |             |         |      |
| Mean±S.D.                               | 62.65±11.87  | 68.78±10.45 | 0.035   | *    |
| Median(range)                           | 65(56-70)    | 68(61-76)   |         |      |
| Sex,n(%)                                |              |             | 0.542   |      |
| Male                                    | 4276.4%      | 1982.6%     |         |      |
| Female                                  | 1323.6%      | 417.4       |         |      |
| Body weight,kg                          |              |             |         |      |
| Mean±S.D.                               | 75.53±12.38  | 81.61±9.302 | 0.038   | *    |
| Median(range)                           | 77(69-83)    | 84(75-88)   |         |      |
| Apache II score on ICU                  |              |             |         |      |
| Mean±S.D.                               | 19.51±2.73   | 19.65±3.60  | 0.849   |      |
| Median(range)                           | 19(18-22)    | 20(17-22)   |         |      |
| SOFA score                              |              |             |         |      |
| Mean±S.D.                               | 13.15±2.41   | 13.17±1.87  | 0.974   |      |
| Median(range)                           | 13[11-15]    | 13[12-14]   |         |      |
| Albumin (g/L)                           |              |             |         |      |
| Mean±S.D.                               | 27.86±5.50   | 28.10±6.53  | 0.867   |      |
| Median(range)                           | 28.0(25.7-32.3) | 29.4(23.7-33.5) |     |      |
| Serum creatinine (μmol/L)               |              |             |         |      |
| Mean±S.D.                               | 62.73±29.81  | 79.00±26.24 | 0.026   | *    |
| Median(range)                           | 50(42-77)    | 76(63-89)   |         |      |
| Clinical Outcomes                       |              |             |         |      |
| Composite outcome of new-onset AKI or RRT | 4(7.3)   | 3(13.0)    | 0.143   | 0.705 |
| Clinical success rate, n (%)            | 39(70.9)     | 19(82.6)    | 1.164   | 0.281 |
| 28-day all-cause mortality              | 4            | 0           | 0.585   | 0.444 |

*p<0.05

Abbreviations: APACHE II, acute physiology and chronic health evaluation II; SOFA, Sequential Organ Failure Assessment; AKI, acute kidney injury; RRT, renal replacement therapy.
Figure 1

Kaplan-Meier curves for (A) Duration of Antibiotics between the two groups before weighting; (B) Duration of Antibiotics between the two groups after weighting; (C) Duration of Ventilation between the two groups before weighting; (D) Duration of Antibiotics between the two groups after weighting; (E) Duration of Mechanical Ventilation between the two groups before weighting; (F) Duration of Mechanical Ventilation between the two groups after weighting.
